Navigation Links
Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting

EMERYVILLE, Calif., Sept. 3 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA on September 13, 2009. The presentation will describe results from a multi-institutional collaborative in vitro study of Adamas' triple combination antiviral drug (TCAD) therapy.

    Presentation details:

    Title:            Triple Combination of Amantadine, Ribavirin and
                      Oseltamivir Restores In Vitro Activity of Antiviral
                      Drugs against Resistant Influenza Viruses

    Date/Time:        Sunday, Sep 13, 2009, 10:45 AM -11:00 AM

    Session:          064-Respiratory Viruses and Influenza
                      Sunday, Sep 13, 2009, 8:30 AM -11:00 AM

    Abstract Number:  V-537b

    Location:         Marriott Salon 9

    Authors:          J. T. NGUYEN (1), J. HOOPES (2), D. SMEE (2),
                      M. LE (1), A. PATICK (1), M. DE JONG (3),
                      G. WENT (1), D. FAIX (4), P. BLAIR (4),
                      M. PRICHARD (5);
                      (1) Adamas Pharmaceuticals, Emeryville, CA,
                      (2) Utah State Univ., Logan, UT,
                      (3) Amsterdam Med. Ctr., Amsterdam, Netherlands,
                      (4) Naval Health Research Center, San Diego, CA,
                      (5) Univ. of Alabama, Birmingham, AL.

About TCAD

Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, acts synergistically to provide a much higher level of antiviral activity than single or double drug combinations. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy for influenza A in North America during this upcoming flu season.

About Adamas

Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics(TM) to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India. For more information about Adamas, please visit

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
(Date:10/13/2015)... SPRINGS, Florida , October 13, 2015 ... AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ), and ... ARRY ), Avanex Life Sciences Corp. (OTCQX: AVXLD), ... Pharmaceuticals, Inc. (NASDAQ: PGNX ) --> ... and the biotech industry can potentially lead to advancements ...
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
(Date:10/13/2015)... ... ... Proove Biosciences, a commercial and research leader ... Medicine of the University of Southern California (USC) Pain Center to study ... Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one of ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
Breaking Biology Technology:
(Date:10/12/2015)... 9, 2015 Research and Markets ( ... new report "Biometrics: Market Shares, Strategies, and Forecasts, ... --> --> The study is ... market segment. Research represents a selection from the mountains ... market materials, with selections made by the most senior ...
(Date:10/8/2015)... Calif. , Oct. 8, 2015 ... of human interface solutions, announced today that it ... of fiscal 2016 on Thursday, October 22, 2015, ... host a corresponding conference call for analysts and ... during which management may discuss forward-looking information.    ...
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
Breaking Biology News(10 mins):